The MAP Group broadens their European market access platform by adding SKC to its portfolio of companies
The MAP Group has continued its international expansion, with the acquisition of SKC Beratungsgesellschaft mbH, significantly increasing expertise and headcount and expanding its footprint into a key European market.
Cambridge, UK, 6 November 2024 – The MAP Group, a pan-European specialist pharmaceutical and biotechnology strategic consultancy focused on driving therapies through the complex medical, regulatory and market access landscape to maximise success in Europe, today announced that it has acquired SKC Beratungsgesellschaft mbH, a strategic consultancy based in Hannover, Germany. SKC, founded in 2005, is the leading German market access and pricing and reimbursement consultancy, and supports pharma, biotech, medtech, and digital health companies with complex strategic issues. The MAP Group has established operations across the UK, Ireland and Benelux, with extensive experience across more than 200 clients in 20 markets.
Steve Glass, the MAP Group CEO, commented “With the addition of the experienced and talented team from SKC, we advance our objective to ensure patient access to life-changing therapies in Europe and beyond. As the implications of the fast-approaching EU-HTA are at stake, this acquisition is an important step to further expand our pan-European presence and support our clients in an ever-changing landscape, with a global perspective and crucial local expertise.”
Earlier this year, the MAP Group acquired the Belgium based consultancy, AxTalis, which broadened the Group’s capabilities, including regulatory strategy and compliance and medical affairs, in addition to strong market access capabilities in the Benelux region that complement well established existing offerings.
SKC co-founder, Matthias P. Schönermark remarked, “Joining the MAP Group provides new exciting opportunities to apply our unique capabilities and drive value across our combined clients and expanded geography. The merging of our talents will drive positive change and broaden access to therapeutic solutions throughout Europe, the UK, and across the globe. This is the perfect basis to build a European market access champion.”
Dr. Matthias P. Schönermark and Heike Kielhorn-Schönermark will join The MAP Group’s Executive Leadership Team and the group’s strategy is to continue to widen its range of products, services and capabilities, as well as geographical reach, through talent and corporate acquisition.
About The MAP Group
The MAP Group is Europe’s largest independent specialist pharmaceutical and biotechnology management consultancy. Its unique capabilities enable companies to maximize the value of their product portfolios, while providing patients with life-changing health solutions, by facilitating access to medicines across Europe’s complex medical, regulatory and payer environment. The MAP Group provides a unique combination of specialist consultancy products and services across the development path to commercialisation, along with an online membership platform providing uninterrupted access to experts as well as an extensive and unique database, set of tools and invaluable content, to a wide range of pharmaceutical and biotech companies across Europe. The MAP Group is headquartered in the United Kingdom, with additional sites across Europe, providing its range of products and services to customers across the globe, and backed by Kester Capital.
For more information about MAP Patient Access, visit www.mappatientaccess.com
The MAP Group
Media Inquiries:
Please contact Marianne Lambertson, Chief Commercial Officer
